Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management confidently projects crossing Rs. 100 crores in consolidated revenue in Q3 FY27, targeting an EBITDA margin exceeding 22% for the quarter.
- The 'Mission 500 Crores' revenue target by 2028 is based purely on organic growth from the existing and newly acquired businesses, without factoring in future M&A.
- Starting Q3, the company will provide a clear split between organic and inorganic growth to improve transparency following recent acquisitions.
Performance Overview
- Jagsonpal Pharmaceuticals accelerated its growth trajectory, aiming to become a Rs. 500-crore organization by 2028 through a combination of organic momentum and strategic acquisitions.
- The company successfully completed two key acquisitions: Equitas Healthcare, providing entry into the hospital channel, and the Group Pharma wellness portfolio, expanding its doctor reach and therapy areas.
- Consolidated financial statements were introduced for the first time, reflecting the integration of the newly acquired Equitas business.
- Organic growth stood at 9.3% for the quarter, with management expressing confidence in future acceleration driven by investments in people, new launches, and stronger execution.
- Power brands demonstrated strong performance, outperforming their respective molecule markets and reinforcing the company's strength in Gynecology, Orthopedics, and Dermatology.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.